Source: Annual Congress 2004 - Inflammation and smoking induced effects
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. M. Zielonka, U. Demkow, M. Filewska, B. Bialas, A. Soszka, J. Kus, E. Rozewska-Skopinska (Warsaw, Poland). The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF). Eur Respir J 2004; 24: Suppl. 48, 3417

Member's Comments

No comment yet.

Related content which might interest you: Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018 Hepatocyte growth factor (HGF) expression in bronchoveolar lower (BAL) does not confirm its anti-fibrotic activity in interstitial lung diseases (ILD) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly? Year: 2007 Down regulation of stromal cell-derived factor 1 (SDF-1/CXCL12) in lung tissue of patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006 The effect of vascular endothelial growth factor (VEGF) on primary human cultured type 2 alveolar epithelial (AE2) cell proliferation Source: Annual Congress 2004 - Cellular injury and repair in the lung Year: 2004 Overexpression of B cell activating factor (BAFF) in peripheral lung of COPD patients Source: Annual Congress 2009 - Pathology and immunology of COPD Year: 2009 Vascular endothelial growth factor (VEGF) levels in induced sputum and plasma in asymptomatic and COPD smokers. Correlation with airway and systemic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 652s Year: 2006 TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity Source: Eur Respir J 2001; 18: Suppl. 33, 410s Year: 2001 Vascular endothelial growth factor (VEGF) isoform expression in primary human cultured alveolar epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 84s Year: 2003 Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Expression of insulin-growth factor-I (IGF-I) in alveolar lymphocytes (AL) in interstitial lung diseases (ILD). Potential functions of AL-derived IGF Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 Effects of hypoxia on VEGF and VEGF-R expression by human alveolar epithelial (ATII) and human pulmonary microvascular endothelial (HMVEC-l) cells Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury Year: 2008 Imbalance between vascular endothelial growth factor and endostatin in emphysema Source: Eur Respir J 2003 Oct 01;22(4):609-612 Year: 2003 Circulating haemopoietic and endothelial progenitor cells are decreased in COPD Source: Eur Respir J 2006; 27: 529-541 Year: 2006 Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003 Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 A comparative study of two angiogenic factors: vascular endothelial growth factor (VEGF) and angiogenin (Ang) in induced sputum from asthmatic children in acute attack Source: Eur Respir J 2006; 28: Suppl. 50, 258s Year: 2006